公開日期 | 標題 | 作者 | 來源出版物 | scopus | WOS | 全文 |
---|---|---|---|---|---|---|
2020 | Phase I dose-escalation and -expansion study of telisotuzumab (ABT-700), an Anti-c-met antibody, in patients with advanced solid tumors | Strickler J.H.; LoRusso P.; Salgia R.; Kang Y.-K.; Yen C.J.; CHIA-CHI LIN ; Ansell P.; Motwani M.; Wong S.; Yue H.; Wang L.; Reilly E.; Afar D.; Naumovski L.; Ramanathan R.K. | Molecular Cancer Therapeutics | 16 | 14 | |
2021 | Randomised Phase 1b/2 trial of tepotinib vs sorafenib in Asian patients with advanced hepatocellular carcinoma with MET overexpression | Ryoo B.-Y.; ANN-LII CHENG ; Ren Z.; Kim T.-Y.; Pan H.; Rau K.-M.; Choi H.J.; Park J.-W.; Kim J.H.; Yen C.J.; Lim H.Y.; Zhou D.; Straub J.; Scheele J.; Berghoff K.; Qin S. | British Journal of Cancer | 20 | 17 |